Literature DB >> 27453622

Investigating the impact of oxygen concentration and blood flow variation on photodynamic therapy.

Rozhin Penjweini1, Michele M Kim2, Jarod C Finlay1, Timothy C Zhu1.   

Abstract

Type II photodynamic therapy (PDT) is used for cancer treatment based on the combined action of a photosensitizer, a special wavelength of light, oxygen (3O2) and generation of singlet oxygen (1O2). Intra-patient and inter-patient variability of oxygen concentration ([3O2]) before and after the treatment as well as photosensitizer concentration and hemodynamic parameters such as blood flow during PDT has been reported. Simulation of these variations is valuable, as it would be a means for the rapid assessment of treatment effect. A mathematical model has been previously developed to incorporate the diffusion equation for light transport in tissue and the macroscopic kinetic equations for simulation of [3O2], photosensitizers in ground and triplet states and concentration of the reacted singlet oxygen ([1O2]rx) during PDT. In this study, the finite-element based calculation of the macroscopic kinetic equations is done for 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide (HPPH)-mediated PDT by incorporating the information of the photosensitizer photochemical parameters as well as the tissue optical properties, photosensitizer concentration, initial oxygen concentration ([3O2]0), blood flow changes and ϕ that have been measured in mice bearing radiation-induced fibrosarcoma (RIF) tumors. Then, [1O2]rx calculated by using the measured [3O2] during the PDT is compared with [1O2]rx calculated based on the simulated [3O2]; both calculations showed a reasonably good agreement. Moreover, the impacts of the blood flow changes and [3O2]0 on [1O2]rx have been investigated, which showed no pronounced effect of the blood flow changes on the long-term 1O2 generation. When [3O2]0 becomes limiting, small changes in [3O2] have large effects on [1O2]rx.

Entities:  

Keywords:  PDT; blood flow changes; in vivo mice models; macroscopic simulation; singlet oxygen generation; tissue oxygenation

Year:  2016        PMID: 27453622      PMCID: PMC4955668          DOI: 10.1117/12.2211120

Source DB:  PubMed          Journal:  Proc SPIE Int Soc Opt Eng        ISSN: 0277-786X


  17 in total

1.  The role of oxygen monitoring during photodynamic therapy and its potential for treatment dosimetry.

Authors:  Josephine H Woodhams; Alexander J Macrobert; Stephen G Bown
Journal:  Photochem Photobiol Sci       Date:  2007-09-21       Impact factor: 3.982

2.  Comparison of PDT parameters for RIF and H460 tumor models during HPPH-mediated PDT.

Authors:  Baochang Liu; Michele M Kim; Shannon M Gallagher-Colombo; Theresa M Busch; Timothy C Zhu
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2014-03-05

3.  Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.

Authors:  Jarod C Finlay; Timothy C Zhu; Andreea Dimofte; Diana Stripp; S Bruce Malkowicz; Theresa M Busch; Stephen M Hahn
Journal:  Photochem Photobiol       Date:  2006 Sep-Oct       Impact factor: 3.421

4.  Direct near-infrared luminescence detection of singlet oxygen generated by photodynamic therapy in cells in vitro and tissues in vivo.

Authors:  Mark Niedre; Michael S Patterson; Brian C Wilson
Journal:  Photochem Photobiol       Date:  2002-04       Impact factor: 3.421

5.  Explicit dosimetry for photodynamic therapy: macroscopic singlet oxygen modeling.

Authors:  Ken Kang-Hsin Wang; Jarod C Finlay; Theresa M Busch; Stephen M Hahn; Timothy C Zhu
Journal:  J Biophotonics       Date:  2010-06       Impact factor: 3.207

6.  Long-term monitoring of live cell proliferation in presence of PVP-Hypericin: a new strategy using ms pulses of LED and the fluorescent dye CFSE.

Authors:  Rozhin Penjweini; Hans G Loew; Michael R Hamblin; Karl W Kratky
Journal:  J Microsc       Date:  2011-10-04       Impact factor: 1.758

Review 7.  Photodynamic therapy for cancer.

Authors:  Dennis E J G J Dolmans; Dai Fukumura; Rakesh K Jain
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

8.  Modifying excitation light dose of novel photosensitizer PVP-Hypericin for photodynamic diagnosis and therapy.

Authors:  Rozhin Penjweini; Hans G Loew; Maria Eisenbauer; Karl W Kratky
Journal:  J Photochem Photobiol B       Date:  2013-01-10       Impact factor: 6.252

9.  The impact of complement activation on tumor oxygenation during photodynamic therapy.

Authors:  Ivana Cecic; Andrew I Minchinton; Mladen Korbelik
Journal:  Photochem Photobiol       Date:  2007 Sep-Oct       Impact factor: 3.421

10.  Singlet oxygen- versus nonsinglet oxygen-mediated mechanisms of sensitizer photobleaching and their effects on photodynamic dosimetry.

Authors:  I Georgakoudi; T H Foster
Journal:  Photochem Photobiol       Date:  1998-06       Impact factor: 3.421

View more
  4 in total

1.  1O2 determined from the measured PDT dose and 3O2 predicts long-term response to Photofrin-mediated PDT.

Authors:  Rozhin Penjweini; Michele M Kim; Yi Hong Ong; Timothy C Zhu
Journal:  Phys Med Biol       Date:  2020-01-24       Impact factor: 3.609

2.  Intracellular oxygen mapping using a myoglobin-mCherry probe with fluorescence lifetime imaging.

Authors:  Rozhin Penjweini; Alessio Andreoni; Tilman Rosales; Jeonghan Kim; Michael D Brenner; Dan L Sackett; Jay H Chung; Jay R Knutson
Journal:  J Biomed Opt       Date:  2018-10       Impact factor: 3.170

Review 3.  Photodynamic viral inactivation: Recent advances and potential applications.

Authors:  Jace A Willis; Vsevolod Cheburkanov; Giulia Kassab; Jennifer M Soares; Kate C Blanco; Vanderlei S Bagnato; Vladislav V Yakovlev
Journal:  Appl Phys Rev       Date:  2021-06       Impact factor: 19.162

4.  Genetically encoded FRET probes for direct mapping and quantification of intracellular oxygenation level via fluorescence lifetime imaging.

Authors:  Alessio Andreoni; Rozhin Penjweini; Branden Roarke; Marie-Paule Strub; Dan L Sackett; Jay R Knutson
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2019-02-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.